Febrile neutropenia risk assessment tool: Improving clinical outcomes for oncology patients

European Journal of Oncology Nursing

Volumn 18, Issue 2, 2014, Pages 167-174

  O'Brien, Catherine ^a   Dempsey, Orla ^b   Kennedy, M John ^a,b  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Chemotherapy; Febrile neutropenia; G CSF; Risk assessment; Risk factors

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER CENTER; CHEMOTHERAPY; COMPARATIVE STUDY; FEBRILE NEUTROPENIA; FEMALE; G-CSF; HUMAN; INTERDISCIPLINARY COMMUNICATION; IRELAND; NEOPLASM; NURSING; NURSING ASSESSMENT; ONCOLOGY NURSING; ORGANIZATION AND MANAGEMENT; PILOT STUDY; PROFESSIONAL COMPETENCE; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

CHEMOTHERAPY; FEBRILE NEUTROPENIA; G-CSF; RISK ASSESSMENT; RISK FACTORS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER CARE FACILITIES; FEBRILE NEUTROPENIA; FEMALE; HUMANS; INTERDISCIPLINARY COMMUNICATION; IRELAND; NEOPLASMS; NURSING ASSESSMENT; ONCOLOGY NURSING; PILOT PROJECTS; PROFESSIONAL COMPETENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84894667715     PISSN: 14623889     EISSN: 15322122     Source Type: Journal    
DOI: 10.1016/j.ejon.2013.11.002     Document Type: Article

References (44)

1. Aapro M.S., Bohlius J., Cameron D.A., Dal Lago L., Donnelly J.P., Kearney N., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European Journal of Cancer 2011, 44(1):8-32. 10.1016/j.ejca.2010.10.013.
2. Aapro M., Crawford J., Kamioner D. Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?. Supportive Care in Cancer 2010, 18(5):529-541. 10.1007/s00520-010-0816-y.
3. Al-Kali A., Ozer H. First-cycle CSF use in breast cancer and NHL: guidelines and recommendations. Oncology 2006, 20(14):1-11.
4. Bennett C.L., Calhoun E.A. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007, 12(4):478-483.
5. Bonadonna G., Moliterni A., Zambetti M., Daidone M.G., Pilotti S., Gianni L., et al. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. British Medical Journal 2005, 330(7485):217-222. 10.1136/bmj.38314.622095.8F.
6. Bosley A., Bron D., Van Hoof A., De Bock R., Berneman Z., Ferrant A., et al. Achievement of optimal relative dose intensity and correlation with survival in diffuse large B-cell lymphoma treated with CHOP. Annals of Hematology 2008, 87(4):277-283. 10.1007/s00277-007-0399-y.
7. Cappozzo C. Optimal use of granulocyte-colony-stimulating factor in patients with cancer who are at risk for chemotherapy-induced neutropenia. Oncology Nursing Forum 2004, 31(3):569-574. 10.1188/04.ONF.569-576.
8. Chan A., Chen C., Chiang J., Tan S., Ng R. Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Supportive Care in Cancer 2012, 20:1525-1532. 10:1007/s00520-011-1241-6.
9. Chirivella I., Bermejo B., Insa A., Perez-Fidalgo A., Magro A., Rosello S., et al. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcomes of breast cancer patients. Breast Cancer Research and Treatment 2009, 114(3):479-484. 10.1007/s10549-008-0018-1.
10. Cooper K.L., Madan J., Whyte S., Stevenson M.D., Akehurst R.L. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 11:404.
11. Crawford J., Armitage J., Balducci L., Becker P., Blayney D., Cataland S., et al. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors; Version 2.2013 2013, NCCN, Fort Washington, Available at:, (accessed 23.02.13.). http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf.
12. Crawford J., Caserta C., Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Annals of Oncology 21 (Supp. 5) 2010, 248-251. 10.1093/annonc/mdq195.
13. Crawford J., Dale D., Kuderer N., Culakova E., Poniewierski M., Wolff D., et al. Risk and timing of neutropenic events in adult patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. Journal of the National Comprehensive Cancer Network 2008, 6(2):109-118.
14. Dale D.C., McCarter G.C., Crawford J., Lyman G.H. Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomised clinical trials. Journal of the National Comprehensive Cancer Network 2003, 1(3):440-454.
15. Dolan S., Crombez P., Munoz M. Neutropenia management with granulocyte colony-stimulating factors: from guidelines to nursing practice protocols. European Journal of Oncology Nursing 2005, 9(Suppl.1):S14-S23.
16. Donohue R.B. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia. Oncology Nursing Forum 2006, 33(2):347-352. 10.1188/06.ONF.347-352.
17. Doyle A.M. Prechemotherapy assessment of neutropenic risk. Oncology Nursing Edition 2006, 20(10):32-40.
18. Flores I.Q., Ershler W. Managing neutropenia in older patients with cancer receiving chemotherapy in a community setting. Clinical Journal of Oncology Nursing 2010, 14(1):81-86. 10.1188/10.CJON.81-86.
19. Freifeld A., Bow E., Sepkowitz K., Boeckh M., Eto J., Mullen C., et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clinical Infectious Diseases 2011, 52(4):e56-e93. 10.1093/cid/cir073.
20. Friedman L., Engelking C., Wickham R., Harvey C., Read M., Bardel Whitlock K. The EDUCATE study: a continuing education exemplar for clinical practice guideline implementation. Clinical Journal of Oncology Nursing 2009, 13(2):219-230. 10.1188/09.CJON.219-230.
21. Griffin D., Penphase B., Klamerus J. Relative dose intensity - improving treatment and outcomes in early-stage breast cancer: a retrospective study. Oncology Nursing Forum 2012, 39(6):e459-e467. 10.1188/12.ONF.E459-E467.
22. Hwa C., Ricci A., Fortenbaugh C., Fallon J., Johnston R., Leahy N. Implementing a multi-symptom chemotherapy risk assessment tool in two community oncology practices. Community Oncology 2007, 4(6):404-409. 10.1016/S1548-5315(11)70148-6.
23. Irish Cancer Society Understanding Chemotherapy: Caring for People with Cancer 2012, Irish Cancer Society, Dublin.
24. Kearney N., Friese C. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: implications for oncology nurses. European Journal of Oncology Nursing 2008, 12(1):14-25. 10.1016/j.ejon.2007.10.001.
25. Khan S., Dhadda A., Fyee D., Sundar S. Impact of neutropenia on delivering planned chemotherapy for solid tumours. European Journal of Cancer Care 2008, 17(1):19-25. 10.1111/j.1365-2354.2007.00797.x.
26. Kuderer N.M., Dale D.C., Crawford J., Cosler L.E., Lyman G.H. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106(10):2258-2266. 10.1002/cncr.21847.
27. Lenhart C. Relative dose intensity: improving cancer treatment outcomes. Oncology Nursing Forum 2005, 32(4):757-764.
28. Loibl S., Scace L.T., Nekljdova V., Luck H., Schwenkglenks M., Brodowicz T., et al. Evaluating the impact of relative total dose intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer - a pooled analysis. BioMed Central Cancer 2011, 11-131. http://www.biomedcentral.com/1471-2407/11/131.
29. Lyman G.H., Shayne M. Granulocyte-colony-stimulating factors: finding the right indication. Current Opinion in Oncology 2007, 19(4):299-307. 10.1097/CCO.0b013e3281a3c0ba.
30. Lyman G.H., Dale D.C., Friedberg J., Crawford J., Fisher R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. Journal of Clinical Oncology 2004, 22(21):4302-4311. 10.1200/JCO.2004.03.213.
31. Lyman G.H., Dale D.C., Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. Journal of Clinical Oncology 2003, 21(24):4524-4531. 10.1200/JCO.2003.05.002.
32. Macmillan Cancer Support AC Chemotherapy 2011, Macmillan Cancer Support, UK, Retrieved from:, on 29 October 2013. http://www.macmillan.org.uk/Cancerinformation/Cancertreatment/Treatmenttypes/Chemotherapy/Combinationregimen/AC.aspx.
33. Maxwell C., Stein A. Implementing evidence-based guidelines for preventing chemotherapy-induced neutropenia: from paper to clinical practice. Community Oncology 2006, 3(8):530-536. 10.1016/S1548-5315(11)70747-1.
34. Maxwell C., Winkler L., Lottenberg M. Nurse driven management guidelines: improving patient outcomes through evidence-based practice. Oncology Nursing Forum 2002, 29(2):371.
35. Miller K. Using a computer-based risk assessment tool to identify risk for chemotherapy-induced febrile neutropenia. Clinical Journal of Oncology Nursing 2010, 14(1):87-91. 10.1188/10.CJON.87-91.
36. Moore K., Johnson G., Fortner B.V., Houts A.C. The AIM higher initiative: new procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. Clinical Journal of Oncology Nursing 2008, 12(2):229-237. 10.1188/08.CJON.229-238.
37. Oladipo O., Coyle V., McAleer J., McKenna S. Achieving optimal dose intensity with adjuvant chemotherapy in elderly breast cancer patients: a 10-year restrospective study in a UK institution. The Breast Journal 2012, 18(1):16-22. 10.1111/j.1524-4741.2011.01177.x.
38. Pettengall R., Schwenkglenks M., Leonard R., Bosly A., Paridaens R., Constenia M., et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Supportive Care in Cancer 2008, 16(11):1299-1309. 10.1007/s00520-008-0430-4.
39. Sarosy G., Hussain M., Seidin M., Fuller A., Nikrui N., Goodman A., et al. Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor prognosis, advanced-stage epithelial ovarian cancer. Cancer 2010, 116(6):1476-1484. 10.1002/cncr.24861.
40. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. Journal of Clinical Oncology 2006, 19(1):3187-3205.
41. Vavra K., Saadeh C., Rosen A., Uptigrove C., Srkalovic G. Improving the relative dose intensity of systemic chemotherapy in a community-based cancer centre. Journal of Oncology Practice 2013, 9(5):e203-e211.
42. Vogel C.L., Wojtukiewicz M.Z., Carroll R.R., Tijulandin S.A., Barajas-Figueroa L.J., Wiens B.L., et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicentre, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2005, 23(6):1178-1184. 10.1200/JCO.2005.09.102.
43. Weycker D., Danel A., Marciniak A., Bendall K., Lipsitz M., Pettengell R. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice. BMC Cancer 2012, 12(1):362. 10.1186/1471-2407-12-362.
44. Wilson B.J., Gardner A.E. Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors. Oncology Nursing Forum 2007, 34(2):347-353. 10.1188/07.ONF.347-353.